LabCorp and Monogram Biosciences are pleased to announce the launch of HCV GenoSure NS3/4A, a protease inhibitor drug resistance assay for the clinical management of patients with hepatitis c.
HCV GenoSure NS3/4A provides a comprehensive sequence-based analysis of a patients hepatitis C virus to assess drug resistance (or susceptibility) to the NS3/4A protease inhibitors, boceprevir, and telaprevir. It also includes a detailed understanding of the viral population for the entire region of non-structural proteins NS3 and NS4A for hepatitis C virus genotype 1a or 1b.
View Complete PDF At NATAP
New Protease Inhibitor (NS3/4A) Drug Resistance Test -
No comments:
Post a Comment